Clearside “Sapphire” CLS1003-301

Status: Currently enrolling

ClinicalTrial.gov Identifier: NCT02980874

CLS1003-301: A Phase 3, randomized, masked, controlled trial to study the Safety and Efficacy of Suprachoroidal CLS-TA in conjunctions with Intravitreal Aflibercept in patients with Retinal Vein Occlusion

Condition: Retinal Vein Occlusion

Study Type: Interventional

Duration: 48 weeks

Eligibility: 

  • Ages: 18 years and older
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information on this study, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.